{"schema_version":"1.0","type":"article","title":"Curium and Lantheus Agree to an Up-to-$8 Billion Merger: Radiopharma Becomes a Full-Stack Business","url":"https://drugnews.com.tw/articles/2026-08-24-curium-lantheus-definitive-merger-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-08-24-curium-lantheus-definitive-merger-en.md","lang":"en","date":"2026-08-24","publish_at":"2026-08-24T08:00:00+08:00","updated_at":"2026-08-24","category":"商業分析系列","topic":"BD / 授權","tags":["Curium","Lantheus","radiopharma","theranostics","PSMA","PYLARIFY","Pluvicto","M&A","nuclear medicine","Taiwan biotech"],"summary":"The $7 billion Curium-Lantheus rumor covered in June became a definitive agreement on August 3: $102.50 in cash plus up to $12.00 per share in CVRs, for total consideration of up to $8 billion. The strategic prize is an integrated chain spanning isotopes, manufacturing, distribution, diagnostics, therapy and U.S. hospital access.","key_points":[],"facts":[],"sections":["00 | The story has moved from a $7 billion rumor to a definitive agreement worth up to $8 billion","01 | Curium needs the U.S. endpoint; Lantheus needs upstream depth and a stronger therapy arm","02 | Half-life does not merely constrain radiopharma; it determines the business model","03 | Theranostics creates radiopharma's most valuable commercial loop","04 | The competitive rule is changing from pipeline assembly to full-chain integration","05 | Taiwan has few direct radiopharma equities, but it does have imaging and nuclear-medicine infrastructure","Conclusion | Radiopharma is no longer a one-pipeline competition","References"],"references":[{"title":"[Facebook","source":"Original Drugnews long-form post, August 24, 2026]","date":"","url":"https://www.facebook.com/61568446257142/posts/122183498798614875"},{"title":"[Lantheus","source":"Curium Announces Definitive Agreement to Merge with Lantheus, August 3, 2026]","date":"","url":"https://investor.lantheus.com/node/17091"},{"title":"[Curium","source":"How we work: manufacturing and distribution network]","date":"","url":"https://www.curiumpharma.com/about/how-we-work/"},{"title":"[ClinicalTrials.gov","source":"ECLIPSE phase 3 study, NCT05204927]","date":"","url":"https://clinicaltrials.gov/study/NCT05204927"},{"title":"[Lantheus","source":"FDA Approval of PYLARIFY TruVu, March 6, 2026]","date":"","url":"https://investor.lantheus.com/news-releases/news-release-details/lantheus-announces-fda-approval-pylarify-truvutm-piflufolastat-f"},{"title":"[Lantheus","source":"2025 shareholder materials: Neuraceq and commercial portfolio]","date":"","url":"https://investor.lantheus.com/static-files/65cb003c-d33a-441c-b1f7-c6ea7768da2a"},{"title":"[Novartis","source":"Full-year 2025 results and Pluvicto sales]","date":"","url":"https://www.novartis.com/news/media-releases/novartis-delivered-high-single-digit-sales-growth-achieved-40-core-margin-and-further-advanced-pipeline-2025"},{"title":"[Eli Lilly","source":"Lilly Completes Acquisition of POINT Biopharma]","date":"","url":"https://investor.lilly.com/news-releases/news-release-details/lilly-completes-acquisition-point-biopharma"},{"title":"[Taiwan GMS","source":"Company profile and nuclear-medicine manufacturing and distribution]","date":"","url":"https://www.gmstw.com.tw/about.php"},{"title":"[Taiwan FDA","source":"Approved AI and machine-learning medical devices]","date":"","url":"https://www.fda.gov.tw/tc/includes/GetFile.ashx?id=f639083041331900606&type=1"},{"title":"[EBM Technologies","source":"PACS, RIS, DICOM and AI medical-imaging services]","date":"","url":"https://www.ebmtech.com/tw/services"}],"images":[{"alt":"Figure 1 | Curium contributes isotope, manufacturing, distribution and therapy capabilities; Lantheus contributes U.S. diagnostics and hospital access","url":"https://drugnews.com.tw/assets/articles/curium-lantheus-definitive-merger-en/figure-01.webp"},{"alt":"Figure 2 | Radiopharma runs on a timed chain from isotope production and labeling through quality control, shielded delivery and hospital use","url":"https://drugnews.com.tw/assets/articles/curium-lantheus-definitive-merger-en/figure-02.webp"},{"alt":"Figure 3 | Find, Fight, Follow: use PSMA PET to identify a patient, deliver targeted radioligand therapy and continue imaging-based follow-up","url":"https://drugnews.com.tw/assets/articles/curium-lantheus-definitive-merger-en/figure-03.webp"},{"alt":"Figure 4 | Radiopharma M&A is moving from buying a single pipeline to integrating isotope supply, manufacturing, distribution, diagnostics, therapy and hospital channels","url":"https://drugnews.com.tw/assets/articles/curium-lantheus-definitive-merger-en/figure-04.webp"}],"cover_image":"https://drugnews.com.tw/assets/articles/curium-lantheus-definitive-merger-en/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-08-24）。Curium and Lantheus Agree to an Up-to-$8 Billion Merger: Radiopharma Becomes a Full-Stack Business。https://drugnews.com.tw/articles/2026-08-24-curium-lantheus-definitive-merger-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-08-24-curium-lantheus-definitive-merger.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}